UK markets open in 4 hours 45 minutes

argenx SE (ARGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
301.65-0.00 (-0.00%)
At close: 11:57AM EST

argenx SE

Willemstraat 5
Breda 4811 AH
Netherlands
31 763 030 488
https://www.argenx.com

Sector(s)
Industry
Full-time employees336

Key executives

NameTitlePayExercisedYear born
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MScCEO & Exec. Director1.14MN/A1972
Mr. R. Keith WoodsChief Operating OfficerN/AN/A1968
Prof. Hans de Haard Ir, Ph.D.Chief Scientific OfficerN/AN/A1960
Mr. Dirk Marcel Leon Beeusaert L.L.M.Gen. CounselN/AN/A1964
Mr. Arjen Lemmen M.Sc.VP of Corp. Devel. & StrategyN/AN/A1985
Mr. Marc SchorpionGlobal Head of HRN/AN/A1958
Dr. David Lacey M.D.Advisor56.72kN/A1952
Dr. Wim Parys M.D.Chief Medical OfficerN/AN/A1960
Ms. Andria WilkGlobal Head of QualityN/AN/A1973
Mr. Karl GubitzChief Financial OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Corporate governance

argenx SE’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.